Cationic lipid compositions targeting angiogenic endothelial...

Details Cationic lipid compositions targeting angiogenic endothelial... Cationic lipid compositions targeting angiogenic endothelial...

2002-11-22

2009-02-24

Kishore, Gollamudi (Department: 1612)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

Reexamination Certificate

active

07494666

ABSTRACT:
Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs which are comprised of promoters which are selectively and exclusively activated in the environment of an angiogenic endothelial cell.

REFERENCES:
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5202352 (1993-04-01), Okada et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5556878 (1996-09-01), Kelley et al.
patent: 5580899 (1996-12-01), Mayhew et al.
patent: 5837283 (1998-11-01), McDonald et al.
patent: 5837682 (1998-11-01), Folkman et al.
patent: 5935937 (1999-08-01), Smith
patent: 5965739 (1999-10-01), Kelley et al.
patent: 6756055 (2004-06-01), McDonald et al.
patent: 7094424 (2006-08-01), McDonald et al.
patent: 7238369 (2007-07-01), McDonald et al.
patent: 2251945 (1997-10-01), None
patent: 2283327 (1998-03-01), None
patent: 416527 (1991-03-01), None
patent: 0 636 363 (1995-02-01), None
patent: 0819758 (1998-01-01), None
patent: WO 91/06309 (1991-05-01), None
patent: WO 91/16024 (1991-10-01), None
patent: WO 93/12240 (1993-06-01), None
patent: WO 93/12756 (1993-07-01), None
patent: WO 93/18751 (1993-09-01), None
patent: WO 93/24640 (1993-12-01), None
patent: WO 93/25673 (1993-12-01), None
patent: WO 95/25543 (1995-09-01), None
patent: 9530330 (1995-11-01), None
patent: WO 95/29242 (1995-11-01), None
patent: WO 00/47235 (2000-08-01), None
Brigham, K.L., et al., (1989) AExpression of a Prokaryotic Gene in Cultured Lung Endothelial Cells after Lipofection with a Plasmid Vector,@ Am. J. Respir. Cell Mol. Biol. 1: 95-100.
Brigham, K.L., et al. (1989) ARapid Communication: In vivo Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle,@ from the Center for Lung Research, Dept. of Med. Path. and Molecular Phys. and Biophys., Vanderbilt U. School of Med., Nashville, Tenn. pp. 278-284.
Burrows, F.J., et al., (1993) AEradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature,@ Proc. Natl. Acad. Sci. USA 90: 8996-9000.
Felgner, P.L., et al., (1991) AGene Therapeutics@ Nature 349: 351-352.
Felgner, P.L., et al., (1987) ALipofection: A highly efficient, lipid-mediated DNA-transfection procedure,@ Proc. Natl. Acad. Sci. USA 84: 7413-7417.
Folkman, J., et al., (1989) AInduction of angiogenesis during the transition from hyperplasia to neoplasia,@ Nature 339: 58-61.
Folkman, J., et al., (1987) AAngiogenic Factors,@ Science 235:442-447.
Gao, X., et al., (1995) ACationic liposome-mediated gene transfer,@ Gene Therapy 2: 710-722.
Hanahan, D., et al., (1996) A Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigensis,@ Cell 86: 333-364.
Huang, X., et al., (1997) ATumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature,@ Science 275: 547-550.
Morishita, K., et al., (1996) AA novel promoter for vascular endothelial growth factor receptor (fit-1) that confers endothelial-specific gene expression,@ J. Biol Chem. 270: 27948-27953.
Xu, N., et al., “Parenteral Gene Therapy with p53 Inhibits Human Breast Tumors in Vivo Through a Bystander Mechanism Without Evidence of Toxicity,” Human Gene Therapy 8:177-185.
Campbell, et al., “Cationic liposome mediated drug delivery”,Biophys. J., (1997) vol. 72(2): A303 (WP313).
McLean, et al., “Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice”,Amer. J. Physiology, vol. 1, part 2, 273:H387-H404.
Wasan, E.K., “Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposome”, Journal of Pharmaceutical Sciences, 85, #4, pp. 427-433, Apr. 1996.
Klauber, et al. “Inhibition of angiogenesis and breast cancer in mice be the microtubule inhibitors 2-methoxyestradiol and Taxol™”,CancerResearch, (1997) vol. 57:81-86.
Isner. “Cancer and atherosclerosis: The broad mandate of angiogenesis”, Circulation, (1999) vol. 99(13): 1653-1655.
Patterson, C., et al. Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. Journal of Biological Chemistry. 1995, vol. 270, No. 39, pp. 23111-23118.
Iwona Wrobel, et al. Biochimica et Biophysica Acta, 1995, vol. 1235, p. 296-304.

Affiliated with

Also associated with

Rating

Cationic lipid compositions targeting angiogenic endothelial... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cationic lipid compositions targeting angiogenic endothelial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cationic lipid compositions targeting angiogenic endothelial... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4111988